MX2022016587A - Bioconjugado tetravalente de shigella (shigella4v). - Google Patents

Bioconjugado tetravalente de shigella (shigella4v).

Info

Publication number
MX2022016587A
MX2022016587A MX2022016587A MX2022016587A MX2022016587A MX 2022016587 A MX2022016587 A MX 2022016587A MX 2022016587 A MX2022016587 A MX 2022016587A MX 2022016587 A MX2022016587 A MX 2022016587A MX 2022016587 A MX2022016587 A MX 2022016587A
Authority
MX
Mexico
Prior art keywords
shigella
tetravalent
shigella4v
bioconjugate
bioconjugates
Prior art date
Application number
MX2022016587A
Other languages
English (en)
Spanish (es)
Inventor
Stefan Jochen Kemmler
Martin Edward Braun
Rainer Follador
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX2022016587A publication Critical patent/MX2022016587A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2022016587A 2020-06-18 2021-06-17 Bioconjugado tetravalente de shigella (shigella4v). MX2022016587A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063040844P 2020-06-18 2020-06-18
US202063043883P 2020-06-25 2020-06-25
EP20182139 2020-06-25
EP20182138 2020-06-25
PCT/IB2021/055361 WO2021255684A1 (en) 2020-06-18 2021-06-17 Shigella-tetravalent (shigella4v) bioconjugate

Publications (1)

Publication Number Publication Date
MX2022016587A true MX2022016587A (es) 2023-02-01

Family

ID=76502778

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016587A MX2022016587A (es) 2020-06-18 2021-06-17 Bioconjugado tetravalente de shigella (shigella4v).

Country Status (8)

Country Link
US (1) US20230346902A1 (cg-RX-API-DMAC7.html)
EP (1) EP4168040A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023530154A (cg-RX-API-DMAC7.html)
CN (1) CN115697396A (cg-RX-API-DMAC7.html)
BR (1) BR112022024294A2 (cg-RX-API-DMAC7.html)
CA (1) CA3185719A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022016587A (cg-RX-API-DMAC7.html)
WO (1) WO2021255684A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026087718A1 (en) * 2024-10-23 2026-04-30 Institut Pasteur A multivalent shigella vaccine and methods of making and using thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DK1481057T3 (da) 2002-03-07 2006-05-15 Eidgenoess Tech Hochschule System og fremgangsmåde til fremstilling af rekombinante glycosylerede proteiner i en prokaryot vært
ES2535084T3 (es) 2005-05-11 2015-05-05 Eth Zurich Proteínas N-glicosiladas recombinantes procedentes de células procariotas
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
US9238830B2 (en) 2006-12-13 2016-01-19 The Governors Of The University Of Alberta Methods and systems for O-glycosylating proteins
SI2257307T1 (sl) 2008-02-20 2018-09-28 Glaxosmithkline Biologicals S.A. Biokonjugati, izdelani iz rekombinantnih N-glikoziliranih proteinov iz prokariontskih celic
CN101569744A (zh) * 2009-01-20 2009-11-04 张鑫 一种细菌性痢疾多价疫苗
NO2501406T3 (cg-RX-API-DMAC7.html) 2009-11-19 2018-05-19
KR20150068998A (ko) * 2012-10-12 2015-06-22 글리코박신 아게 숙주 세포 변형 방법
EP2917351B1 (en) * 2012-11-07 2018-12-19 GlaxoSmithKline Biologicals S.A. Production of recombinant vaccine in e. coli by enzymatic conjugation
NZ723328A (en) 2014-02-24 2018-01-26 Glycovaxyn Ag Compositions comprising e. coli o25b antigen, uses thereof and methods of manufacture
CN106659799B (zh) * 2014-07-25 2020-07-17 碧奥辛斯有限责任公司 用于制备针对因肠致病性细菌引起的感染的广谱疫苗的包含表达内置的多个表位的分子构建体的基本单元的糖缀合物疫苗
CN105695497B (zh) 2014-11-27 2019-09-24 中国人民解放军军事医学科学院生物工程研究所 一种细菌多糖修饰的重组融合蛋白的制备方法及其应用
CN114796472A (zh) * 2015-06-16 2022-07-29 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition

Also Published As

Publication number Publication date
EP4168040A1 (en) 2023-04-26
WO2021255684A1 (en) 2021-12-23
BR112022024294A2 (pt) 2023-02-28
CN115697396A (zh) 2023-02-03
CA3185719A1 (en) 2021-12-23
US20230346902A1 (en) 2023-11-02
JP2023530154A (ja) 2023-07-13

Similar Documents

Publication Publication Date Title
PH12023553205A1 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
GEP20247633B (en) Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
GEAP202316334A (en) Nanoemulsion adjuvant composition for pneumococcal conjugate vaccines
EP4656208A3 (en) Methods for making polysaccharide-protein conjugates
PL411824A1 (pl) Zastosowanie kompozycji zawierającej monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22
EA035991B9 (ru) Новый полисахарид и его применения
MY182282A (en) Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
MX2022005452A (es) Conjugados farmaco-anticuerpo dirigidos a la claudina 18.2.
MX2019013605A (es) Material botanico homogeneizado que comprende un modificador de ph basico.
AR118389A1 (es) Métodos de producción de bioconjugados de polisacáridos de e. coli o-antígeno, sus composiciones y métodos de utilización
NO20005672L (no) Svekkede Salmonella-mutanter som konstitutivt uttrykker Vi- antigenet
CY1115710T1 (el) Ρευστο παρασκευασμα που περιλαμβανει ενα συμπλοκο πιμοβενδανης και κυκλοδεξτρινης
MX2021014710A (es) Un conjugado inmunogenico de polisacarido de neumococo del serotipo 35b- proteina y proceso de conjugacion para preparar el mismo.
MX2022015734A (es) Proteinas de exotoxina a modificadas.
TR200200065T2 (tr) Dış salgılama bozukluklarının tedavisi için terkip
BG107220A (en) Antitumoral ecteinascudin derivatives
ZA202101663B (en) Purified capsular polysaccharides of streptococcus pneumoniae
MX2024008039A (es) Composiciones inmunogenicas que comprenden antigenos de sacaridos capsulares conjugados y usos de los mismos.
NO20026242L (no) Syntesemetoder for aplidin og nye antitumorale derivater, metoder for deresfremstilling og anvendelse av disse
AR105010A1 (es) Composiciones inmunógenas
CL2023000740A1 (es) Composiciones de vacunas multivalentes y usos de las mismas.
MX2022014249A (es) Composición farmacéutica para tratar el cáncer.
MX2023013665A (es) Polipeptidos del sars-cov-2.
AU9385501A (en) Vectors for molecule delivery to cd11b expressing cells
MX2020009935A (es) Formulaciones acuosas y estables de anticuerpos anti-tau.